These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38754786)

  • 1. Evaluation of two inoculation routes of an adenovirus-mediated viral protein inhibitor in a Crimean-Congo hemorrhagic fever mouse model.
    Scholte FEM; Spengler JR; Welch SR; Harmon JR; Coleman-McCray JD; Davies KA; Pegan SD; Montgomery JM; Spiropoulou CF; Bergeron É
    Virus Res; 2024 Jul; 345():199398. PubMed ID: 38754786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stable Occupancy of the Crimean-Congo Hemorrhagic Fever Virus-Encoded Deubiquitinase Blocks Viral Infection.
    Scholte FEM; Hua BL; Spengler JR; Dzimianski JV; Coleman-McCray JD; Welch SR; McMullan LK; Nichol ST; Pegan SD; Spiropoulou CF; Bergeron É
    mBio; 2019 Jul; 10(4):. PubMed ID: 31337717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heat Shock Protein 70 Family Members Interact with Crimean-Congo Hemorrhagic Fever Virus and Hazara Virus Nucleocapsid Proteins and Perform a Functional Role in the Nairovirus Replication Cycle.
    Surtees R; Dowall SD; Shaw A; Armstrong S; Hewson R; Carroll MW; Mankouri J; Edwards TA; Hiscox JA; Barr JN
    J Virol; 2016 Oct; 90(20):9305-16. PubMed ID: 27512070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.
    Hinkula J; Devignot S; Åkerström S; Karlberg H; Wattrang E; Bereczky S; Mousavi-Jazi M; Risinger C; Lindegren G; Vernersson C; Paweska J; van Vuren PJ; Blixt O; Brun A; Weber F; Mirazimi A
    J Virol; 2017 May; 91(10):. PubMed ID: 28250124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus-Derived DNA Forms Mediate the Persistent Infection of Tick Cells by Hazara Virus and Crimean-Congo Hemorrhagic Fever Virus.
    Salvati MV; Salaris C; Monteil V; Del Vecchio C; Palù G; Parolin C; Calistri A; Bell-Sakyi L; Mirazimi A; Salata C
    J Virol; 2021 Nov; 95(24):e0163821. PubMed ID: 34613808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bovine Herpesvirus Type 4 (BoHV-4) Vector Delivering Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus Induces Comparable Protective Immunity against Lethal Challenge in IFNα/β/γR-/- Mice Models.
    Aligholipour Farzani T; Földes K; Hanifehnezhad A; Yener Ilce B; Bilge Dagalp S; Amirzadeh Khiabani N; Ergünay K; Alkan F; Karaoglu T; Bodur H; Ozkul A
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30857305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and evaluation of neutralizing and fusion inhibitory peptides to Crimean-Congo hemorrhagic fever virus.
    Mears MC; Rodriguez SE; Schmitz KS; Padilla A; Biswas S; Cajimat MNB; Mire CE; Welch SR; Bergeron É; Alabi CA; Porotto M; Bente DA
    Antiviral Res; 2022 Nov; 207():105401. PubMed ID: 36049554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crimean-Congo Hemorrhagic Fever Mouse Model Recapitulating Human Convalescence.
    Hawman DW; Meade-White K; Haddock E; Habib R; Scott D; Thomas T; Rosenke R; Feldmann H
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31292241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Insights into Crimean-Congo Hemorrhagic Fever Virus.
    Zivcec M; Scholte FE; Spiropoulou CF; Spengler JR; Bergeron É
    Viruses; 2016 Apr; 8(4):106. PubMed ID: 27110812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38.
    Mishra AK; Moyer CL; Abelson DM; Deer DJ; El Omari K; Duman R; Lobel L; Lutwama JJ; Dye JM; Wagner A; Chandran K; Cross RW; Geisbert TW; Zeitlin L; Bornholdt ZA; McLellan JS
    J Virol; 2020 Mar; 94(8):. PubMed ID: 31996434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crimean-Congo hemorrhagic fever virus nucleocapsid protein harbors distinct RNA-binding sites in the stalk and head domains.
    Jeeva S; Mir S; Velasquez A; Ragan J; Leka A; Wu S; Sevarany AT; Royster AD; Almeida NA; Chan F; O'Brien L; Mir MA
    J Biol Chem; 2019 Mar; 294(13):5023-5037. PubMed ID: 30723154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside-Modified mRNA Vaccines Protect IFNAR
    Appelberg S; John L; Pardi N; Végvári Á; Bereczky S; Ahlén G; Monteil V; Abdurahman S; Mikaeloff F; Beattie M; Tam Y; Sällberg M; Neogi U; Weissman D; Mirazimi A
    J Virol; 2022 Feb; 96(3):e0156821. PubMed ID: 34817199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and selective inhibition of pathogenic viruses by engineered ubiquitin variants.
    Zhang W; Bailey-Elkin BA; Knaap RCM; Khare B; Dalebout TJ; Johnson GG; van Kasteren PB; McLeish NJ; Gu J; He W; Kikkert M; Mark BL; Sidhu SS
    PLoS Pathog; 2017 May; 13(5):e1006372. PubMed ID: 28542609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocompetent mouse model for Crimean-Congo hemorrhagic fever virus.
    Hawman DW; Meade-White K; Leventhal S; Feldmann F; Okumura A; Smith B; Scott D; Feldmann H
    Elife; 2021 Jan; 10():. PubMed ID: 33416494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model.
    Saunders JE; Gilbride C; Dowall S; Morris S; Ulaszewska M; Spencer AJ; Rayner E; Graham VA; Kennedy E; Thomas K; Hewson R; Gilbert SC; Belij-Rammerstorfer S; Lambe T
    EBioMedicine; 2023 Apr; 90():104523. PubMed ID: 36933409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-omics insights into host-viral response and pathogenesis in Crimean-Congo hemorrhagic fever viruses for novel therapeutic target.
    Neogi U; Elaldi N; Appelberg S; Ambikan A; Kennedy E; Dowall S; Bagci BK; Gupta S; Rodriguez JE; Svensson-Akusjärvi S; Monteil V; Vegvari A; Benfeitas R; Banerjea A; Weber F; Hewson R; Mirazimi A
    Elife; 2022 Apr; 11():. PubMed ID: 35437144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models.
    Garrison AR; Shoemaker CJ; Golden JW; Fitzpatrick CJ; Suschak JJ; Richards MJ; Badger CV; Six CM; Martin JD; Hannaman D; Zivcec M; Bergeron E; Koehler JW; Schmaljohn CS
    PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005908. PubMed ID: 28922426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Crimean-Congo Hemorrhagic Fever Virus and Aigai Virus in Life Cycle Modeling Systems Reveals a Difference in L Protein Activity.
    Pickin MJ; Devignot S; Weber F; Groschup MH
    J Virol; 2022 Jul; 96(13):e0059922. PubMed ID: 35695578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of 2'-deoxy-2'-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus.
    Welch SR; Scholte FEM; Flint M; Chatterjee P; Nichol ST; Bergeron É; Spiropoulou CF
    Antiviral Res; 2017 Nov; 147():91-99. PubMed ID: 29024765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ISG15 overexpression compensates the defect of Crimean-Congo hemorrhagic fever virus polymerase bearing a protease-inactive ovarian tumor domain.
    Devignot S; Kromer T; Mirazimi A; Weber F
    PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008610. PubMed ID: 32931521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.